205Bi/206Bi cyclotron production from Pb-isotopes for absorption studies in humans
References (24)
- et al.
The large-scale production of carrier-free 206Bi for medical application
Int. J. Appl. Radiat. Isot.
(1975) - et al.
Cyclotron Production of no-carrier-added 206Bi (6.24d) and 205Bi (15.31d) as tracers for biological studies and for the development of alpha-emitting radiotherapeutic agents
Appl. Radiat. Isot.
(1987) - et al.
Cinetique et distribution du 206Bi chez le rat et le lapin: un modele
Int. J. Appl. Radiat. Isot.
(1983) - et al.
Cross sections of (p, xn) reactions in the isotopes of lead and bismuth
Can. J. Phys.
(1956) - et al.
Radiation dosimetry of 204Bi- and 206Bi-citrates
J. Nucl. Med.
(1976) - et al.
Encephalopathies myocloniques per les sels de bismuth
Nouv. Presse Medicale
(1974) - et al.
Long-term retention of 207Bi in the human body after injection of 206Bi
Health Phys.
(1985) - et al.
The distribution of intravenously administered tracer doses of Bi-206 compounds in the human body
J. Belge Radiol.
(1961) - et al.
Bioavailability of bismuth from 205Bi-labelled pharmaceutical oral Bi-preparations in rats
Arch. Toxicol.
(1991) - et al.
Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease
Scand. J. Gastroenterol.
(1992)
Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate
Eur. J. Clin Pharmac.
(1989)
Nuclear Orientation and NMR/ON of 205,207Po
Z. Phys. A Atoms Nuclei
(1983)
Cited by (3)
In Vivo evaluation of newly synthesized <sup>213</sup>Bi-conjugated alpha-melanocyte stimulating hormone (α-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model
2023, Journal of Pharmaceutical and Biomedical AnalysisBoosting Bismuth(III) Complexation for Targeted α-Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**
2022, Angewandte Chemie - International Edition
Copyright © 1993 Published by Elsevier Ltd.